Drugs / R78C
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05385471 | Jan 2023 → Mar 2026 overdue | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06958198 | Sep 2025 → Oct 2026 expected | Plasmodium falciparum malaria | University of Oxford | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07183371 | Dec 2025 → Dec 2026 expected | Plasmodium falciparum malaria | University of Oxford | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-25 | Serum Institute of India Pvt. Ltd. | University of Oxford and Serum Institute of India Agree Licence to Advance the Next-Generation Multi-Stage Malaria Vaccine Candidate Component R78C seruminstitute.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R78C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07183371 ↗ |
| Modality | Vaccine | “candidate malaria vaccines R78C and RH5.1 formulated in adjuvant Matrix-M” NCT05385471 ↗ |
| Route | Intramuscular | “All volunteers will be given 10 µg R78C and/or 10 µg RH5.1 soluble protein in combination with 50 µg of Matrix-M via intramuscular (IM) injection in the deltoid region of the...” NCT05385471 ↗ |